Beta Drugs Ltd

- No major debt increase is planned for FY27 and FY28; expected borrowings are modest with working capital utilization around INR7-10 crores and term loans close to INR20 crores. - Compulsory convertible debentures (CCD) are set to convert to equity by May 2026, reducing interest expenses significantly. - Capex requirements for the next two years are low (not more than INR25 crores), minimizing the need for new debt. - Currently, there is around INR100 crores cash on hand, and management is open to acquisitions if opportunities arise, but no immediate plans or options are in hand. - No explicit mention of upcoming equity fundraising; focus is on organic growth and strategic acquisitions if opportunities arise. - Interest cost expected to reduce post CCD conversion, with normal bank interest rates around 7.5-8% on existing loans. Overall, Beta Drugs does not anticipate substantial new fundraising through debt or equity in the near term.

- Beta Drugs invested around INR45 crores last year across three plants, including land purchase for R&D and corporate office which was later dropped in favor of an office building adjacent to current facilities (Page 9). - The intermediate plant was acquired for INR9 crores with an additional investment of INR15-17 crores; this plant is expected to commercialize by end of this year (Page 9). - Total planned capex for the next two years is not expected to exceed INR25 crores, primarily towards the intermediate plant (Page 9). - No major capex planned beyond that, indicating stable capital expenditure outlook (Page 9). - The company is open to strategic acquisitions if exciting opportunities arise but currently has no options in hand (Page 6). - The intermediate plant is aimed at reducing dependency on imports and improving margins slightly by 1 to 1.5 basis points when commercialized (Pages 9-10).

- Beta Drugs targets 20% to 25% annual sales growth over the next 3-4 years, aiming to more than double sales to around INR 850-900 crores by 2030. - Export revenues are expected to grow at least 50% in the current year with a medium-term target of reaching INR 200-250 crores by FY28. - Exports are anticipated to contribute about 30% of total revenue by FY30. - The cosmetology and dermatology division aims for 30%-40% annual growth for the next 3-4 years. - The newly acquired Nivian IVF/fertility business is expected to grow at 30% annually over the next 3-4 years. - Beta plans to launch 20-25 new oncology products over the next 3-4 years to drive branded sales growth of 20%-25%. - CDMO business aims for steady growth of 5%-6% annually in the coming years. - Improvement in production capacities and new intermediate API plant commercialization is expected to enhance margins and growth.

- Beta Drugs aims to grow sales at 20% to 25% annually over the next 4 years, targeting INR850-900 crores revenue by 2030 (Page 15). - The company expects a doubling of sales from current levels in the next 4 years (Page 15). - EBITDA margins are expected to improve above 23%-24%, supported by growth in exports and branded sales (Page 5). - Export revenues are projected to grow substantially, with 50% growth expected in FY27 due to delayed tender awards being cleared (Page 15, 13). - The newly acquired Nivian fertility business consolidation from FY27 will add revenue, with an 18-19% EBITDA margin and 9-10% PAT margin (Page 6). - Capex plans for next 2 years are modest (INR 25 crores), implying leveraged growth from existing assets supporting INR700-800 crores peak revenues without major investment (Page 9). - Interest costs will reduce significantly post-debenture conversion in May 2026, aiding profitability (Page 9).

- As of Q1 FY27, Beta Drugs has around 50% of export orders in hand for the upcoming quarter. - The company expects to fulfill existing orders and is also anticipating new orders and tenders. - Pending export tenders that were delayed and missed in FY26 have now been awarded in March 2026, with supplies starting from Q1 FY27. - These delayed tenders had an estimated revenue impact of INR 20-25 crores. - The company has laid strategies to focus on other high-margin products amid challenges in Platen sales. - Export orders for the current quarter are expected to be around INR 20-22 crores, with solid growth anticipated in subsequent quarters. - Overall, the order book visibility is healthy with orders in hand and an expectation of additional new tenders.